Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak

Tanrıverdi, Özgür

doi:10.1007/s12032-020-01376-8

Cited by 6 publications

(4 citation statements)

References 3 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is followed by a late stimulation of respiratory DCs to the lymph nodes chain with an insufficient virus-specific T cell response [ 45 ]. In patients infected with SARS-CoV-2, there is a start of lymphopenia, and the lymphocyte count is an estimate of disease danger and death-rate [ 46 ]. Lymphocyte levels recover with viral removal and the control of the disease, along with adaptive immune cells (CD3+ T cells) exist particularly significant [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approach

Akachar¹,

Bouricha²,

Hakmi³

et al. 2020

Heliyon

View full text Add to dashboard Cite

The coronavirus disease 19 (COVID-19) is a highly contagious and rapidly spreading infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In some cases, the disease can be fatal which resulted in more than one million deaths worldwide according the WHO. Currently, there is no effective vaccine or treatment for COVID-19, however many small-molecule inhibitors have shown potent antiviral activity against SARS-CoV-2 and some of them are now under clinical trials. Despite their promising activities, the development of these small molecules for the clinical use can be limited by many factors like the off-target effect, the poor stability, and the low bioavailability. The clusters of differentiation CD147, CD209, CD299 have been identified as essential entry co-receptors for SARS-CoV-2 species specificity to humans, although the underlying mechanisms are yet to be fully elucidated. In this paper, protein-protein docking was utilized for identifying the critical epitopes in CD147, CD209 and CD299 which are involved in the binding with SARS-CoV-2 Spike receptor binding domain (RBD). The results of binding free energies showed a high affinity of SARS-CoV-2 RBD to CD299 receptor which was used as a reference to derive hypothetical peptide sequences with specific binding activities to SARS-CoV-2 RBD. Molecular docking and molecular dynamics simulations of the newly designed peptides showed favorable binding features and stability with SARS-CoV-2 RBD and therefore can be further considered as potential candidates in future anti-SARS CoV-2 drug discovery studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approach

Akachar¹,

Bouricha²,

Hakmi³

et al. 2020

Heliyon

View full text Add to dashboard Cite

show abstract

“…28 Lymphopenia is associated with an increased risk of opportunistic infections (a significant implication during the present pandemic), and worse oncologic outcomes due to the lymphocytes' essential roles within the anti-tumor immune response. 29,30 Finally, the present times may represent a boost for further investigation regarding IL-6 targeting in cancer patients.…”

Section: F I G U R Ementioning

confidence: 93%

“…Moreover, this treatment‐induced pro‐inflammatory microenvironment could lead to lymphocyte deficiency 28 . Lymphopenia is associated with an increased risk of opportunistic infections (a significant implication during the present pandemic), and worse oncologic outcomes due to the lymphocytes' essential roles within the anti‐tumor immune response 29,30 …”

Section: Cancer and Il‐6mentioning

confidence: 99%

A bond between rheumatic diseases and cancer in the elderly: The interleukin‐6 pathway

et al. 2021

View full text Add to dashboard Cite

Interleukin (IL)-6 is a soluble factor secreted by T lymphocytes, involved in antibody generation by B lymphocytes. The IL-6 pathway has risen as a pivotal pathway implicated in immune regulation and dysregulation in various rheumatic diseases.Nonetheless, elevated IL-6 levels can also play a role in cancer. Targeting the IL-6 pathway has led to innovative therapeutic approaches for rheumatic diseases and for COVID-19, particularly in the elderly. Indeed, tocilizumab, an agent targeting IL-6, has recently amassed significant attention as a promising univocal agent for different conditions. In this viewpoint, we sought to recall and describe the common pathway among osteoarthritis, rheumatoid arthritis, and cancer, suggesting that anti-IL-6 may be considered a jack-of-all-trades against inflammaging in the elderly.

show abstract

“…While the efficacy of mRNA vaccines for SARS-CoV-2 was not affected by the immunosuppression in cancer patients, the relationship between ICI and humoral response to mRNA vaccines in cancer patients needs to be investigated [18]. The lymphopenia occurs in treatment with temozolomide, ICIs, or other anti-cancer drugs, which may negatively affect the mortality with COVID-19 [19]. As COVID-19 affects global concern, many cancer drugs including monoclonal antibodies, antibody-drug conjugates, CAR-T cell therapies, and ICIs have been approved in the COVID-19 pandemic [20].…”

Section: Icis and Covid-19mentioning

confidence: 99%

Relationship Between Corona Virus Infection And Immune Checkpoint Inhibitors

Tanabe¹

2022

Genesis

View full text Add to dashboard Cite

The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) causes infectious disease, COVID-19, and the relationship between COVID-19 and cancer immunotherapy such as immune checkpoint inhibitors (ICIs) is not fully understood. Recent rapid progress in ICI therapy has reported their immune response-related reaction, which demonstrates the importance of studies on the relationship between ICIs and COVID-19. In this Editorial, the application of ICIs in COVID-19 is focused on.

show abstract

Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak

Cited by 6 publications

References 3 publications

Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approach

Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approach

A bond between rheumatic diseases and cancer in the elderly: The interleukin‐6 pathway

Relationship Between Corona Virus Infection And Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About